Cell and Gene Therapy (CGT): KOL Perspectives on Precision Medicine, AI, and the Future of Advanced Therapeutics
A Cell and Gene Therapy KOL perception study exploring the future of Advanced Therapeutics, Precision Medicine, AI in Cell and Gene Therapy, Gene Editing, Biomarker-guided Therapy, Cell Therapy Manufacturing, reimbursement challenges, emerging technologies, and evolving Cell and Gene Therapy Trends shaping the global Cell and Gene Therapy Market.
Introduction
Cell and Gene Therapy Landscape
Cell and Gene Therapy (CGT) is rapidly transforming the future of medicine by delivering highly personalized and potentially curative treatments across hematologic malignancies, rare genetic disorders, and emerging autoimmune disease indications. Continuous advances in Gene Editing, engineered cell therapies, Precision Medicine, and novel delivery technologies are reshaping clinical practice and accelerating innovation across the global Cell and Gene Therapy Market.
Recent Cell and Gene Therapy Trends highlight increasing adoption of next-generation therapeutic platforms, including allogeneic cell therapies, CAR-NK Therapy, in vivo gene editing, improved viral and non-viral delivery systems, and Biomarker-guided Therapy. Together with advances in Genomic Diagnostics and molecular profiling, these innovations are enabling more precise patient selection, improved treatment effectiveness, and broader application of Advanced Therapeutics.
To better understand these evolving trends, SPER Market Research conducted a Cell and Gene Therapy KOL perception study across the United States and Europe. The study gathered expert insights regarding current clinical adoption, emerging technologies, manufacturing scalability, reimbursement, patient access, Gene Therapy Development, and the Future of Cell and Gene Therapy.
The findings demonstrate strong confidence in continued CGT Innovation while emphasizing that Manufacturing Challenges in CGT, reimbursement complexity, long-term safety monitoring, affordability, and equitable patient access remain key barriers that must be addressed to support sustainable market expansion.
Primary Objective
To assess expert perspectives on the evolving Cell and Gene Therapy landscape, including clinical adoption, CGT Innovation, emerging technologies, manufacturing scalability, patient access, Biomarker-guided Therapy, reimbursement challenges, and future therapeutic directions across oncology, autoimmune diseases, and rare genetic disorders while evaluating the Future of Cell and Gene Therapy and emerging Cell and Gene Therapy Trends.
Respondent Profile
This study provides strategic market intelligence on Precision Medicine, Gene Therapy Development, Cell Therapy Manufacturing, AI in Cell and Gene Therapy, Biomarker-driven Patient Selection, Gene Editing technologies, reimbursement trends, and Emerging Innovations in Gene Therapy shaping the global Cell and Gene Therapy Market.
Executive Summary
What Cell and Gene Therapy KOLs Highlighted
Transformative Impact
KOLs agree that Cell and Gene Therapy is transforming treatment paradigms by providing potentially curative options across hematologic malignancies, selected rare genetic disorders, and emerging autoimmune diseases.
Future Innovation
Experts expect next-generation CGTs—including Gene Editing, CAR-NK Therapy, allogeneic therapies, and improved delivery platforms—to significantly expand future treatment opportunities.
Precision Medicine
Precision Medicine, Genomic Diagnostics, Biomarker-guided Therapy, and Biomarker-driven Patient Selection are viewed as critical enablers for improving treatment effectiveness and clinical outcomes.
Adoption Challenges
Cell Therapy Manufacturing, reimbursement, affordability, long-term safety monitoring, and patient access remain the primary barriers limiting broader Cell and Gene Therapy adoption.
Overall, KOLs believe continued CGT Innovation, AI in Cell and Gene Therapy, Gene Therapy Development, Precision Medicine, and scalable manufacturing technologies will accelerate the Future of Cell and Gene Therapy while driving sustained growth across the global Cell and Gene Therapy Market.
Survey Results Summary
Cell and Gene Therapy KOL Survey Results
| Q# | Survey Question | Primary Objective | Most Common Response | % of KOLs |
|---|---|---|---|---|
| 1 | How significant is the unmet need for improved therapies despite recent advances in CGT? | Assess unmet clinical need | Very High / High unmet need | 84% |
| 2 | Are currently approved cell and gene therapies adequately addressing treatment needs? | Evaluate satisfaction with current therapies | Partially adequate; further innovation required | 78% |
| 3 | What has been the most significant advancement in CGT over the past five years? | Identify major innovations | Gene editing and next-generation cell therapies | 66% |
| 4 | How important is biomarker- and genomic-guided patient selection in maximizing CGT effectiveness? | Assess Precision Medicine importance | Extremely important | 92% |
| 5 | Do you expect CGT indications to expand substantially over the next five years? | Evaluate future market expansion | Yes | 86% |
| 6 | What is the greatest barrier to broader CGT adoption? | Identify key challenges | Manufacturing scalability, reimbursement, cost & patient access | 60% |
| 7 | How likely are AI and digital technologies to improve CGT development and patient selection? | Assess digital transformation | Likely / Very likely | 76% |
| 8 | How optimistic are you about the long-term future of Cell and Gene Therapy? | Assess future outlook | Optimistic / Very optimistic | 90% |
Detailed Response Distribution
Detailed Findings from the Cell and Gene Therapy KOL Perception Study
Experts continue to report significant unmet clinical need despite recent advances in Cell and Gene Therapy.
- 84% reported high or very high unmet clinical need.
- Greatest needs remain across solid tumors, autoimmune diseases and rare genetic disorders.
Most KOLs believe current Cell and Gene Therapy treatments provide meaningful benefit but require continued innovation.
- 78% selected partially adequate.
- Experts emphasized continued innovation in Gene Therapy Development and next-generation therapies.
Gene Editing and next-generation cell therapies were viewed as the most important recent breakthroughs.
- 66% identified Gene Editing as the biggest innovation.
- Experts highlighted continued CGT Innovation across multiple technology platforms.
Precision Medicine remains fundamental for maximizing Cell and Gene Therapy effectiveness.
- 92% selected extremely important.
- Genomic Diagnostics and Biomarker-driven Patient Selection will remain central to future CGTs.
Most experts expect Cell and Gene Therapy applications to expand rapidly over the next five years.
- 86% expect substantial market expansion.
- Growth will be driven by Gene Editing, CAR-NK Therapy and allogeneic cell therapies.
Manufacturing scalability, reimbursement and affordability remain the largest barriers to widespread Cell and Gene Therapy adoption.
- 60% identified Manufacturing Challenges in CGT and reimbursement as the leading barriers.
- Improving scalability will be essential for future market growth.
AI and digital technologies are expected to accelerate Cell and Gene Therapy development and patient selection.
- 76% believe AI will improve Cell and Gene Therapy development.
- Applications include biomarker discovery, patient identification, clinical trial optimization and manufacturing.
Experts remain highly optimistic regarding the future of Cell and Gene Therapy.
- 90% remain optimistic about the Future of Cell and Gene Therapy.
- Continued CGT Innovation, Gene Editing, CAR-NK Therapy and scalable manufacturing are expected to transform patient care.
Key Conclusions
Key Insights from the Cell and Gene Therapy KOL Perception Study
1. Significant Unmet Clinical Need Persists
84% of KOLs believe substantial unmet medical needs remain despite recent advances in Cell and Gene Therapy, particularly across solid tumors, autoimmune diseases under active clinical investigation, and complex rare genetic disorders. These findings reinforce the continued need for innovation throughout the rapidly evolving Cell and Gene Therapy Market.
2. Precision Medicine Will Drive Future Success
92% of respondents consider Genomic Diagnostics, Biomarker-guided Therapy, precision diagnostics, and Biomarker-driven Patient Selection essential for maximizing treatment efficacy, improving safety, and delivering better patient outcomes. Experts agree that Precision Medicine in Cell and Gene Therapy will remain central to the next generation of personalized therapies.
3. Continued Expansion of Cell and Gene Therapy
86% of experts expect Cell and Gene Therapy applications to expand significantly over the next five years, reflecting strong Cell and Gene Therapy Market Trends 2026 driven by advances in:
- Gene Editing technologies
- Allogeneic ("off-the-shelf") Cell Therapies
- CAR-NK Therapy
- In vivo Gene Editing
- Improved Viral & Non-Viral Delivery Systems
- Precision Medicine approaches
These innovations are expected to accelerate the development of Next-generation Cell Therapies while strengthening the Future of Cell and Gene Therapy.
4. Digital Technologies Will Accelerate Development
76% of KOLs believe AI in Cell and Gene Therapy, genomic analytics, digital pathology, predictive modeling, and advanced data platforms will continue improving:
- Biomarker Discovery
- Patient Identification
- Clinical Trial Optimization
- Cell Therapy Manufacturing Efficiency
- Treatment Personalization
Experts also highlighted the expanding role of AI in accelerating Cell Therapy Development and supporting Gene Therapy Development from discovery through commercialization.
5. Long-Term Outlook Remains Highly Positive
90% of KOLs remain optimistic about the long-term future of Cell and Gene Therapy, citing continued CGT Innovation across:
- CRISPR-based Gene Editing
- Base and Prime Editing Technologies
- Next-generation CAR-T Therapy & CAR-NK Therapy
- Allogeneic and iPSC-derived Cell Therapies
- In vivo Gene Editing
- Safer Delivery Platforms
- Scalable Cell Therapy Manufacturing
- Expanded applications across Oncology, Autoimmune Diseases and Rare Genetic Disorders
Collectively, these advancements are expected to establish Advanced Therapeutics as one of the defining pillars of modern healthcare over the coming decade.
Executive Insight
Future of Cell and Gene Therapy
The survey indicates that while current Cell and Gene Therapy approaches have established a strong foundation for treating several high-burden diseases, the next phase of growth will depend on continued advances in Cell Therapy Manufacturing, CGT Reimbursement, Biomarker-driven Patient Selection, next-generation therapeutic platforms, and scalable commercialization strategies.
Key Opinion Leaders across the United States and Europe remain highly optimistic that continued CGT Innovation, AI in Cell and Gene Therapy, Precision Medicine, and ongoing Gene Therapy Development will broaden the clinical impact of Advanced Therapeutics while making these treatments more accessible, efficient, and applicable across a much wider range of diseases over the next decade.
These Cell and Gene Therapy KOL Perspectives provide valuable strategic insights into the evolving Cell and Gene Therapy Market, highlighting the emerging Cell and Gene Therapy Trends expected to shape future innovation, commercialization, patient access, and global adoption.
FAQs
Frequently Asked Questions
What is Cell and Gene Therapy?
Cell and Gene Therapy (CGT) is an advanced therapeutic approach that modifies or replaces cells and genetic material to treat or potentially cure diseases such as cancer, autoimmune disorders, and rare genetic diseases.
Why is Precision Medicine important in Cell and Gene Therapy?
Precision Medicine combines Genomic Diagnostics and Biomarker-guided Therapy to identify the right patients for the right treatment, improving safety, efficacy, and long-term outcomes.
What are the biggest challenges facing Cell and Gene Therapy?
Major challenges include Cell Therapy Manufacturing scalability, reimbursement, high treatment costs, regulatory complexity, patient identification, and long-term safety monitoring.
How is AI transforming Cell and Gene Therapy?
AI supports biomarker discovery, genomic analysis, patient selection, clinical trial optimization, manufacturing efficiency, and treatment personalization, accelerating the overall Gene Therapy Development process.
Which emerging technologies are expected to drive future CGT innovation?
Experts identified Gene Editing, CAR-NK Therapy, allogeneic Cell Therapies, in vivo Gene Editing, improved viral and non-viral delivery systems, and next-generation Cell Therapies as the most promising innovations.
What is the future outlook for Cell and Gene Therapy?
The future of Cell and Gene Therapy is highly promising, with continued advances in Precision Medicine, Gene Therapy Development, AI, scalable manufacturing, and Advanced Therapeutics expected to expand access and improve patient outcomes worldwide.
